Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. In this study, we evaluated the Digital Alzheimer’s Disease Diagnosis (DADD) model, a digital twin framework that extracts neurodegeneration-related digital biomarkers from non-invasive recordings such as electroencephalography (EEG), mapping early functional neural alterations to latent parameters linked to structural AD mechanisms. DADD was applied to a cohort of 459 participants with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), evaluating its performance against established AD biomarkers like APOE genotype, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers in predicting prognostic outcomes over a 10-year follow-up. Digital biomarkers demonstrated strong prognostic value, predicting participants who converted at follow-up, significantly outperforming standard EEG metrics. They also robustly forecast both risk and timing of clinical conversion, matching the performance of established AD biomarkers and even outperforming them in SCD participants. Moreover, combining established AD biomarkers with digital biomarkers led to a significant increase in prognostic accuracy. DADD represents a robust clinical tool, enabling scalable, affordable, non-invasive AD detection and prognostic stratification across diverse clinical settings.

Key findings

Why it matters

This study evaluated a digital twin framework that extracts biomarkers from non-invasive EEG recordings in 459 participants with subjective cognitive decline or mild cognitive impairment over a 10-year follow-up. The digital biomarkers predicted conversion and matched or outperformed established Alzheimer disease biomarkers, and combining them with established biomarkers increased prognostic accuracy.

Study details

How this study scored 39/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 39 of 100.39 of 100 points earned61 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (npj Digital Medicine)
Journal's citation record 2 / 4 Npj Digital Medicine: journal h-index 167 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 459 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Alberto Mazzoni: h-index 33 (OpenAlex, whole career)
Institution's track record 1 / 3 Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 39 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Amato, L. G., Scheijbeler, E. P., van Nifterick, A. M., Lassi, M., de Haan, W., Gouw, A. A., et al. (2026). Predicting Alzheimer progression using EEG-based digital twins. npj Digital Medicine. https://doi.org/10.1038/s41746-026-02997-5

Vancouver

Amato LG, Scheijbeler EP, van Nifterick AM, Lassi M, de Haan W, Gouw AA, et al. Predicting Alzheimer progression using EEG-based digital twins. npj Digital Medicine. 2026. doi:10.1038/s41746-026-02997-5.

BibTeX

@article{amato2026-4670ee3a,
  author  = {Amato, Lorenzo Gaetano and Scheijbeler, Elliz P. and van Nifterick, Anne M and Lassi, Michael and de Haan, Willem and Gouw, Alida A. and Mazzoni, Alberto},
  title   = {{Predicting Alzheimer progression using EEG-based digital twins}},
  journal = {npj Digital Medicine},
  year    = {2026},
  doi     = {10.1038/s41746-026-02997-5},
  url     = {https://doi.org/10.1038/s41746-026-02997-5}
}

Related studies in Genetics

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Genetics

See all studies in Genetics →